Once-monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial

Transplantation. 2013 Jan 27;95(2):e6-e10. doi: 10.1097/TP.0b013e3182782f3a.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anemia / blood
  • Anemia / drug therapy*
  • Anemia / etiology
  • Biomarkers / blood
  • Chi-Square Distribution
  • Chronic Disease
  • Darbepoetin alfa
  • Drug Administration Schedule
  • Erythropoietin / administration & dosage
  • Erythropoietin / adverse effects
  • Erythropoietin / analogs & derivatives*
  • Female
  • Hematinics / administration & dosage*
  • Hematinics / adverse effects
  • Hemoglobins / metabolism
  • Humans
  • Kidney Transplantation* / adverse effects
  • Male
  • Middle Aged
  • Polyethylene Glycols / administration & dosage*
  • Polyethylene Glycols / adverse effects
  • Renal Insufficiency, Chronic / blood
  • Renal Insufficiency, Chronic / complications
  • Renal Insufficiency, Chronic / drug therapy*
  • Spain
  • Time Factors
  • Treatment Outcome

Substances

  • Biomarkers
  • Hematinics
  • Hemoglobins
  • continuous erythropoietin receptor activator
  • Erythropoietin
  • Darbepoetin alfa
  • Polyethylene Glycols

Associated data

  • ClinicalTrials.gov/NCT00605345